--- title: "NovaBridge Biosciences (NBP) news: offering" url: "https://aibio.space/companies/novabridge-biosciences/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "NBP offering news: I-Mab (now NovaBridge Biosciences) cites $61.2 million net from August offering. NovaBridge Biosciences (NASDAQ: NBP), United States." --- NBP NovaBridge Biosciences NASDAQ · United States # NovaBridge Biosciences (NBP) news NBP offering news Financings · 2025-08-20 ## [I-Mab (now NovaBridge Biosciences) cites $61.2 million net from August offering](https://aibio.space/news/i-mab-now-novabridge-biosciences-cites-61-2-million-net-august/) Pro-forma cash of about $226.8 million assumes the August offering, which added 76,666,659 ordinary shares. Reported cash and short-term investments were lower at June 30 than at the end of 2024, and the lead drug's efficacy data come from 10 of 12 patients. ## Latest NovaBridge Biosciences news 1. 2025-07-17 Mergers [I-Mab (now NovaBridge Biosciences) to buy Bridge Health Biotech for $1.8 million upfront](https://aibio.space/news/i-mab-now-novabridge-biosciences-buy-bridge-health-biotech-1-8-million/) The deal gives the company rights tied to the antibody in its lead drug candidate, givastomig, and removes royalties owed on it. The efficacy figure behind the program is early and comes from a dose escalation study of 17 patients. 2. 2025-07-11 Financings [I-MAB (now NovaBridge Biosciences) lifts ADS sale limit to $50,000,000](https://aibio.space/news/i-mab-now-novabridge-biosciences-lifts-ads-sale-limit-50-000-000/) The amendment raises the amount of American depositary shares the company may sell under a sales agreement with Leerink Partners. It has not sold any under the agreement so far. 3. 2025-06-12 Listings [I-Mab (now NovaBridge Biosciences) regains Nasdaq minimum bid price compliance](https://aibio.space/news/i-mab-now-novabridge-biosciences-regains-nasdaq-minimum-bid-price/) Nasdaq notified the company on June 11, 2025. Its American Depositary Shares will stay listed and traded on Nasdaq. ## NovaBridge Biosciences at a glance - **Ticker**: NBP - **Listing**: NASDAQ - **Country**: United States - **Cash, Dec 31, 2025**: $210.8 million ### Related companies - [Travere Therapeutics](https://aibio.space/companies/travere-therapeutics/) NASDAQ: TVTX - [Skye Bioscience](https://aibio.space/companies/skye-bioscience/) NASDAQ: SKYE - [Biomea Fusion](https://aibio.space/companies/biomea-fusion/) NASDAQ: BMEA - [Viking Therapeutics](https://aibio.space/companies/viking-therapeutics/) NASDAQ: VKTX - [NextCure](https://aibio.space/companies/nextcure/) NASDAQ: NXTC - [Exelixis](https://aibio.space/companies/exelixis/) NASDAQ: EXEL - [Gossamer Bio](https://aibio.space/companies/gossamer-bio/) NASDAQ: GOSS - [Lipocine](https://aibio.space/companies/lipocine/) NASDAQ: LPCN ### Also on NASDAQ - [IB Acquisition](https://aibio.space/companies/ib-acquisition/) IBAC - [Oric Pharmaceuticals](https://aibio.space/companies/oric-pharmaceuticals/) ORIC - [Bioventus](https://aibio.space/companies/bioventus/) BVS - [Liquidia](https://aibio.space/companies/liquidia/) LQDA - [CapsoVision](https://aibio.space/companies/capsovision/) CV - [Ocular Therapeutix](https://aibio.space/companies/ocular-therapeutix/) OCUL ## NovaBridge Biosciences annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$62.9 million](https://www.sec.gov/Archives/edgar/data/1778016/000177801626000002/) | [$21.8 million](https://www.sec.gov/Archives/edgar/data/1778016/000177801626000002/) | | Net income (loss) | [-$46.3 million](https://www.sec.gov/Archives/edgar/data/1778016/000177801626000002/) | [-$22.2 million](https://www.sec.gov/Archives/edgar/data/1778016/000177801626000002/) | | Cash and equivalents | [$210.6 million](https://www.sec.gov/Archives/edgar/data/1778016/000177801626000002/) | [$68.3 million](https://www.sec.gov/Archives/edgar/data/1778016/000177801626000002/) | | Short-term investments | [$210,000](https://www.sec.gov/Archives/edgar/data/1778016/000177801626000002/) | [$105.1 million](https://www.sec.gov/Archives/edgar/data/1778016/000177801626000002/) | Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $210.6 million, plus short-term investments of $210,000, $210.8 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about NovaBridge Biosciences Has NovaBridge Biosciences raised money recently? Our latest story on this, dated Aug 20, 2025: "I-Mab (now NovaBridge Biosciences) cites $61.2 million net from August offering". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/i-mab-now-novabridge-biosciences-cites-61-2-million-net-august/). What is the ticker symbol of NovaBridge Biosciences? NovaBridge Biosciences trades under the ticker NBP on NASDAQ. Where is NovaBridge Biosciences listed? NovaBridge Biosciences is listed on NASDAQ. What is the SEC CIK of NovaBridge Biosciences? The SEC Central Index Key (CIK) for NovaBridge Biosciences is 1778016. Its filings are on SEC EDGAR. How many shares does NovaBridge Biosciences have outstanding? 265,377,891 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-04-07. Which country or territory is NovaBridge Biosciences listed under? Our directory records NovaBridge Biosciences under United States. What does NovaBridge Biosciences do? Our directory classifies NovaBridge Biosciences as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of NovaBridge Biosciences? The ISIN recorded for NovaBridge Biosciences is US44975P1030. Does aibio.space cover NovaBridge Biosciences? aibio.space lists NovaBridge Biosciences among 2,820 public biotech companies and publishes its news here as stories appear. Where is NovaBridge Biosciences incorporated? SEC records list its state or country of incorporation as E9. Is NovaBridge Biosciences profitable? NovaBridge Biosciences reported a net loss of $46.3 million for the fiscal year ended Dec 31, 2025, per its annual report to the SEC. How much does NovaBridge Biosciences spend on research and development? $62.9 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does NovaBridge Biosciences have? $210.8 million in cash and short-term investments at Dec 31, 2025, per its 20-F. What is the latest NovaBridge Biosciences (NBP) stock news? Our latest story on NovaBridge Biosciences, dated Aug 20, 2025: "I-Mab (now NovaBridge Biosciences) cites $61.2 million net from August offering". Pro-forma cash of about $226.8 million assumes the August offering, which added 76,666,659 ordinary shares. Reported cash and short-term investments were lower at June 30 than at the end of 2024, and the lead drug's efficacy data come from 10 of 12 patients. [Source](https://aibio.space/news/i-mab-now-novabridge-biosciences-cites-61-2-million-net-august/). How long will NovaBridge Biosciences's cash last? From our story of Aug 20, 2025: The company says its existing cash and short-term investments, together with the net proceeds, will be sufficient to fund operating expenses and capital expenditures through the fourth quarter of 2028, including a randomized Phase 2 trial of givastomig. [Source](https://aibio.space/news/i-mab-now-novabridge-biosciences-cites-61-2-million-net-august/). ## Investor discussion: NovaBridge Biosciences Members talk about NovaBridge Biosciences (NBP). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at NovaBridge Biosciences, newest first. Each line links the filing it comes from. 1. 2025-08-20 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1778016/000177801625000009/imab-ex99_1.htm) 2. 2025-08-04 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1778016/000119312525172122/d846500dex991.htm) 3. 2025-07-17 Mergers Reported a merger or acquisition agreement. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1778016/000095017025096437/imab-ex99_1.htm) 4. 2025-07-11 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1778016/000119312525158201/d32469d424b5.htm) 5. 2025-06-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1778016/000095017025085117/imab-ex99_1.htm) 6. 2025-03-21 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1778016/000095017025043263/imab-ex99_1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:NBP on TradingView](https://www.tradingview.com/symbols/NASDAQ-NBP/). ## SEC filings and registration - **SEC name**: NovaBridge Biosciences - **CIK**: 1778016 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: NBP (Nasdaq) - **State or country of incorporation**: E9 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer - **Business address**: SUITE 400, 2440 RESEARCH BLVD, ROCKVILLE, MD, 20850 - **Phone**: (301) 670 2800 - **Shares outstanding**: 265,377,891 as of 2025-12-31 (20-F filed 2026-04-07) - **Former names**: I-Mab ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1778016/000119312526419669/6-k_-_vs_102.htm) filed 2026-10-13 - [6-K](https://www.sec.gov/Archives/edgar/data/1778016/000119312526384356/6-k_agm.htm) filed 2026-09-08 - [6-K](https://www.sec.gov/Archives/edgar/data/1778016/000119312526384355/6-k_new_director_martin.htm) filed 2026-09-08 - [6-K](https://www.sec.gov/Archives/edgar/data/1778016/000119312526357819/nbp-20260630.htm) filed 2026-08-20 - [6-K](https://www.sec.gov/Archives/edgar/data/1778016/000119312526357817/nbp_-_6-k_for_corporate_.htm) filed 2026-08-20 - [6-K](https://www.sec.gov/Archives/edgar/data/1778016/000119312526316242/6-k_-_2026_agm.htm) filed 2026-07-24 - [6-K](https://www.sec.gov/Archives/edgar/data/1778016/000119312526306688/6-k_-_2026_esop.htm) filed 2026-07-17 - [6-K](https://www.sec.gov/Archives/edgar/data/1778016/000119312526286812/6-k_-_appointment_of_sri.htm) filed 2026-06-29 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001778016), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details NovaBridge Biosciences is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NBP, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: NovaBridge Biosciences - **Ticker**: NBP - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US44975P1030 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-NBP/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/novabridge-biosciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "NovaBridge Biosciences (NBP) news: offering", 2026-10-31, https://aibio.space/companies/novabridge-biosciences/